Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No problem, good luck with them
Oh oh..here comes the $1.30's..sold my small position early this morning
I have to agree..dead money for sometime..may drop below a dollar without some outside financing
Why isn't the stock price going up with so much great news..I know, the pot heads in CA haven't woken up yet
Where's the buying since the news is so good? Well Time what's your answer
Yes but what are they going to do with the debt, the debt and the debt? It will probably close in the red today
Will hit the $1.30's before it goes to $1.80 that is if it ever goes to $1.80 again..it's got holes in that thar ship
They have problems and I will not be adding until/if they work out their finances
"The net loss for the second quarter of 2018 was $22.7 million, or $0.16 per share, compared to the $35.3 million net loss in the second quarter of 2017 or $0.35 per share". Estimates were for -.20 Not bad..improving..now a + CC and I will be adding tomorrow
Second Quarter Results
For the second quarter of 2018, Afrezza net revenue was $3.8 million, an increase of 142% compared to $1.5 million for the second quarter of 2017 resulting from increased volume, price, and favorable cartridge mix. On January 1, 2018, we adopted ASC 606, the new revenue recognition standard, under which we recognize revenue as we sell product to wholesale distributors; revenue for prior periods is recognized on the basis of a model that estimates the sale of Afrezza to patients.
Cost of goods sold remained level for the three months ended June 30, 2018 at $5.0 million compared to the same period in 2017. Lower inventory write-offs offset an increase in cost of goods sold resulting from higher Afrezza sales and excess capacity costs.
Research and development (R&D) expenses for the second quarter of 2018 were $2.9 million compared to $3.1 million for the second quarter of 2017, a decrease of $0.2 million or 5%, reflecting $0.7 million in lower salary related expenses for personnel who were engaged in research and development activities in 2017 who have transitioned to Afrezza medical affairs activities and a $0.3 million decrease in repairs and maintenance on laboratory equipment, offset by a $0.9 million increase in clinical trial costs.
Selling, general and administrative (SG&A) expenses were $21.7 million for the second quarter of 2018 compared to $18.6 million for the second quarter of 2017. The $3.1 million, or 17%, increase was primarily due to a $1.0 million increase in non-cash stock compensation expenses, a $0.8 million increase in consulting fees, a $0.6 million increase in costs related to transitioning certain corporate support functions from Connecticut to our corporate headquarters in California, and a $0.6 million increase in relocation spending for key personnel.
The net loss for the second quarter of 2018 was $22.7 million, or $0.16 per share, compared to the $35.3 million net loss in the second quarter of 2017 or $0.35 per share.
I'll try to be optimistic here....maybe why MNKD is releasing their earnings earlier than usual is so they can give the one two punch, i.e., they release good news today-Thursday and they know the numbers are going to be great tomorrow...I know it's a stretch but who knows...we will see
Down she goes..
Pistol: What's your take on the sell-off from $1.90+ in the last 30 days
You're welcome
Good luck
Like I said, I have a very small position and if the #'s are bad, I wait and possibly buy more later on...how's your position holding up?
Your missing the point....if it drops more and they start improving their #'s I would buy more but will not jump in with both feet..pre market down 3.82%
I sold my position at an average of $1.96 and have save over $10,000 and bought a very little position at $1.47 just in case we get a pop...that's all...I can buy more if they put out + news and the numbers on Friday are good...will still have time to buy in but very cautious right now
5:00 ET today....they better announce some + news and than + numbers tomorrow may send the stock price to $2 or higher if not, the price goes down into the $1.30 range IMO
The company has to have blow out numbers next week or we go down below 2
It's tomorrow and you're right...they better exceed expectations or down we go
Really?
I'm thinking someone in the know is buying ahead of conference on Thursday
What's up??
Will go lower if their conference doesn't have some "BIG POSITIVE NEWS" and their numbers on Friday are not surprising to the up side...Just my opinion...will not buy any more shares until then..bought some at 1.47..This is a make or break week for MNKD IMO
Right again...trading in the 1.40's....this week is going to be huge regarding news...that is why I think the stock price could have a big bounce either way with their numbers this week
Just took a little position
Will buy back in when it goes to $1.42 or lower..already saved over $10,000 selling in the mid $1.90's
Or today
Keep your powder dry...will probably see the $1.40's this week. aimho
WHY?
Not a very flattering article in Saturday's WSJ re: JCP...we will see what the stock price does Monday
I'll be buying back in when it hits $1.41 for a quick pop
It's passed your 500,000
You can put so much lipstick on a pig but it's still a pig
Don't think so..here comes the $1.40's
MannKind and Tanner Pharma Group Enter into an ex-U.S. Distribution Agreement for Afrezza®
You mean August 2 at 5:00 PM ET
Not good...$1.40's soon as I've stated
Is it possible mnkd will perform another RS or file for bankruptcy?